Shots:

• The US FDA has granted BTD to the Roche’s mosunetuzumab for the treatment of adult patients with r/r FL- prior treated with at least two systemic therapies
• The BT designation is based on P-I/Ib GO29781 study assessing mosunetuzumab in R/R non-Hodgkin lymphoma. The safety profile of the therapy was consistent with its mechanism of action
• Mosunetuzumab is an investigational CD20xCD3 T-cell engaging bispecific that targets CD20 on the surface of B-cells and CD3 on the surface of T-cells- being evaluated in clinical development program across several lymphoma indications both as monothx. and combination therapy

Click here to read full press release/ article 

Ref: Roche | Image: Roche